SEC Comment Letter for Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704) (CLRB) — Dec 22, 2010
Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704)
Date: Dec. 22, 2010 · CIK: 0001279704 · Accession: 0000000000-10-076866
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-119366
Letter
Re: Novelos Therapeutics, Inc. Form 10-K Filed March 30, 2010 File No. 333-119366 Dear Mr. Palmin: We have reviewed your filing and have the following comment. Please respond to this letter within ten busin ess days or advise us when you will provide the requested response. If you do not believ e our comment applies to your facts and circumstances, please tell us why in your response. After reviewing the information you provide in response to this comment, we may have additional comments. Form 10-K, filed March 30, 2010
December 22, 2010
Harry S. Palmin President and Chief Executive Officer Novelos Therapeutics, Inc. One Gateway Center, Suite 504 Newton, Massachusetts 02458
Licenses/Collaborations, page 9
1. Please include as an exhibit in your 2010 Form 10-K, your agreement with Lee’s Pharm, or alternatively, tell us the basis for your belief that you are not required to file the agreement pursuant to Item 601(b )(10)(ii)(B) of Regulation S-K.
We urge all persons who are responsible for th e accuracy and adequacy of the disclosure in the filing to be certain that the filing include s the information the Securities Exchange Act of 1934 and all applicable Exchange Act rules requir e. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made. In responding to our comment, please provide a written statement from the company acknowledging that: • the company is responsible for the adequacy and accuracy of the disclo sure in the filing;
Harry S. Palmin Novelos Therapeutics, Inc. December 22, 2010 Page 2
• staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
• the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federa l securities laws of the United States.
You may contact Johnny Gharib at (202) 551-3170 or me at (202) 551-3715 with any questions. Sincerely,
Jeffrey Riedler Assistant Director
Show Raw Text
December 22, 2010 Harry S. Palmin President and Chief Executive Officer Novelos Therapeutics, Inc. One Gateway Center, Suite 504 Newton, Massachusetts 02458 Re: Novelos Therapeutics, Inc. Form 10-K Filed March 30, 2010 File No. 333-119366 Dear Mr. Palmin: We have reviewed your filing and have the following comment. Please respond to this letter within ten busin ess days or advise us when you will provide the requested response. If you do not believ e our comment applies to your facts and circumstances, please tell us why in your response. After reviewing the information you provide in response to this comment, we may have additional comments. Form 10-K, filed March 30, 2010 Licenses/Collaborations, page 9 1. Please include as an exhibit in your 2010 Form 10-K, your agreement with Lee’s Pharm, or alternatively, tell us the basis for your belief that you are not required to file the agreement pursuant to Item 601(b )(10)(ii)(B) of Regulation S-K. We urge all persons who are responsible for th e accuracy and adequacy of the disclosure in the filing to be certain that the filing include s the information the Securities Exchange Act of 1934 and all applicable Exchange Act rules requir e. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made. In responding to our comment, please provide a written statement from the company acknowledging that: • the company is responsible for the adequacy and accuracy of the disclo sure in the filing; Harry S. Palmin Novelos Therapeutics, Inc. December 22, 2010 Page 2 • staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and • the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federa l securities laws of the United States. You may contact Johnny Gharib at (202) 551-3170 or me at (202) 551-3715 with any questions. Sincerely, Jeffrey Riedler Assistant Director